Tyra Biosciences (TYRA) Cash from Financing Activities (2020 - 2026)
Quarterly Cash from Financing Activities rose 7233.47% to $160.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $166.3 million through Mar 2026, up 4048.07% year-over-year, with the annual reading at $8.1 million for FY2025, 95.99% down from the prior year.
Tyra Biosciences filings provide 7 years of Cash from Financing Activities readings, the most recent being $160.4 million for Q1 2026.
- Cash from Financing Activities hit $160.4 million in Q1 2026 for Tyra Biosciences, up from $4.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $200.3 million in Q1 2024 and bottomed at $3000.0 in Q4 2022.
- Average Cash from Financing Activities over 5 years is $21.9 million, with a median of $467000.0 recorded in 2023.
- The largest annual shift saw Cash from Financing Activities tumbled 99.82% in 2022 before it soared 53175.27% in 2024.
- Tyra Biosciences' Cash from Financing Activities stood at $3000.0 in 2022, then surged by 10700.0% to $324000.0 in 2023, then surged by 117.9% to $706000.0 in 2024, then skyrocketed by 563.31% to $4.7 million in 2025, then skyrocketed by 3324.79% to $160.4 million in 2026.
- Per Business Quant, the three most recent readings for TYRA's Cash from Financing Activities are $160.4 million (Q1 2026), $4.7 million (Q4 2025), and $647000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - | 160.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160.38 Mn |
| Mar 31, 2026 | 160.38 Mn |
| Dec 31, 2025 | 4.68 Mn |
| Dec 31, 2025 | 4.68 Mn |
| Sep 30, 2025 | 647,000.00 |
| Sep 30, 2025 | 647,000.00 |
| Jun 30, 2025 | 583,000.00 |
| Jun 30, 2025 | 583,000.00 |
| Mar 31, 2025 | 2.19 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 706,000.00 |
| Dec 31, 2024 | 706,000.00 |
| Sep 30, 2024 | 743,000.00 |
| Sep 30, 2024 | 743,000.00 |
| Jun 30, 2024 | 373,000.00 |
| Jun 30, 2024 | 373,000.00 |
| Mar 31, 2024 | 200.32 Mn |
| Mar 31, 2024 | 200.32 Mn |
| Dec 31, 2023 | 324,000.00 |
| Dec 31, 2023 | 324,000.00 |
| Sep 30, 2023 | 467,000.00 |
| Sep 30, 2023 | 467,000.00 |
| Jun 30, 2023 | 370,000.00 |
| Jun 30, 2023 | 370,000.00 |
| Mar 31, 2023 | 376,000.00 |
| Mar 31, 2023 | 376,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Sep 30, 2022 | 364,000.00 |
| Sep 30, 2022 | 364,000.00 |
| Jun 30, 2022 | 27,000.00 |
| Jun 30, 2022 | 27,000.00 |
| Mar 31, 2022 | 238,000.00 |
| Mar 31, 2022 | 238,000.00 |
| Dec 31, 2021 | -1.51 Mn |
| Dec 31, 2021 | -1.51 Mn |
| Sep 30, 2021 | 183.44 Mn |
| Sep 30, 2021 | 183.44 Mn |
| Jun 30, 2021 | -733,000.00 |
| Jun 30, 2021 | -733,000.00 |
| Mar 31, 2021 | 130.15 Mn |
| Mar 31, 2021 | 130.15 Mn |
| Dec 31, 2020 | -4,000.00 |
| Dec 31, 2020 | -4,000.00 |